ADP-receptor inhibitors in the perioperative period: The good, the bad, and the ugly

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 27, Issue 4, 2013, Pages 779-795

  Oprea, Adriana Dana ^a   Popescu, Wanda M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADP receptor inhibitors; cangrelor; clopidogrel; perioperative period; prasugrel; ticagrelor

Indexed keywords

2 (2 CHLOROPHENYL) 2 (4,5,6,7 TETRAHYDROTHIENO[3,2 C]PYRIDIN 5 YL)ACETIC ACID; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CANGRELOR; CARBOXYLIC ACID; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DRUG METABOLITE; ELINOGREL; EPTIFIBATIDE; ERYTHROMYCIN; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; OMEPRAZOLE; PANTOPRAZOLE; PRASUGREL; PRODRUG; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; RABEPRAZOLE; TICAGRELOR; TICLOPIDINE; TIROFIBAN;

AGRANULOCYTOSIS; APLASTIC ANEMIA; BARE METAL STENT; BIOAVAILABILITY; BLEEDING; BRAIN HEMORRHAGE; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DENTAL PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; EYE SURGERY; GASTROINTESTINAL HEMORRHAGE; HALF LIFE TIME; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART SURGERY; HUMAN; INFUSION RATE; KIDNEY FUNCTION; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); METABOLITE; MULTICENTER STUDY (TOPIC); NEUTROPENIA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ORTHOPEDIC SURGERY; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REBOUND; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX SURGERY; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSTABLE ANGINA PECTORIS; UROLOGIC SURGERY; VASCULAR SURGERY; VERTEBRAL ARTERY STENOSIS;

ADP RECEPTOR INHIBITORS; CANGRELOR; CLOPIDOGREL; PERIOPERATIVE PERIOD; PRASUGREL; TICAGRELOR;

ADENOSINE; CARDIAC SURGICAL PROCEDURES; HEMORRHAGE; HUMANS; PERIOPERATIVE CARE; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2; RECEPTORS, PURINERGIC P2Y12; SURGICAL PROCEDURES, OPERATIVE; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84880267277     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2012.11.014     Document Type: Review

References (185)

1. G.W. Stone, and H.D. Aronow Long-term care after percutaneous coronary intervention: Focus on the role of antiplatelet therapy Mayo Clin Proc 81 2006 641 652
2. J.J. Nawarskas, and S.M. Clark Ticagrelor: A novel reversible oral antiplatelet agent Cardiol Rev 19 2011 95 100
3. P. Gladding, M. Webster, and J. Ormiston Antiplatelet drug nonresponsiveness Am Heart J 155 2008 591 599
4. N.A. Farid, A. Kurihara, and S.A. Wrighton Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans J Clin Pharmacol 50 2010 126 142
5. T. DiPerri, F.L. Pasini, and C. Frigerio Pharmacodynamics of ticlopidine in man in relation to plasma and blood cell concentration Eur J Clin Pharmacol 41 1991 429 434
6. J. Kuzniar, B. Splawinska, and K. Malinga Pharmacodynamics of ticlopidine: Relation between dose and time of administration to platelet inhibition Int J Clin Pharmacol Ther 34 1996 357 361
7. C. Picard-Fraire Ticlopidine hydrochloride: Relationship between dose, kinetics, plasma concentration and effect on platelet function Thromb Res Suppl 4 1983 119 128
8. L. Wallentin P2Y(12) inhibitors: Differences in properties and mechanisms of action and potential consequences for clinical use Eur Heart J 30 2009 1964 1977
9. M.J. Quinn, and D.J. Fitzgerald Ticlopidine and clopidogrel Circulation 100 1999 1667 1672
10. P.H. Slugg, D.R. Much, and W.B. Smith Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel J Clin Pharmacol 40 2000 396 401
11. G. Deray, C. Bagnis, and R. Brouard Clopidogrel activities in patients with renal function impairment Clin Drug Investig 16 1998 319 328
12. Sanofi-Aventis Canada Inc. Plavix, 2012. Available at: http://products.sanofi.ca/en/plavix.pdf. Accessed August 14, 2012
13. R. Hall, and C.D. Mazer Antiplatelet drugs: A review of their pharmacology and management in the perioperative period Anesth Analg 112 2011 292 318
14. W. Hochholzer, D. Trenk, and D. Frundi Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention Circulation 111 2005 2560 2564
15. D.L. Bhatt Prasugrel in clinical practice N Engl J Med 361 2009 940 942
16. S.D. Wiviott, E.M. Antman, and E. Braunwald Prasugrel Circulation 122 2010 394 403
17. M.T. Martin, S.A. Spinler, and E.A. Nutescu Emerging antiplatelet therapies in percutaneous coronary intervention: A focus on prasugrel Clin Ther 33 2011 425 442
18. D.S. Small, R.E. Wrishko, and C.S. Ernest Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease J Clin Pharm Ther 34 2009 585 594
19. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
20. R.E. Wrishko, C.S. Ernest, and D.S. Small Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38 J Clin Pharmacol 49 2009 984 998
21. C. Trumel, B. Payrastre, and M. Plantavid A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase Blood 94 1999 4156 4165
22. 12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels Arterioscler Thromb Vasc Biol 24 2004 1810 1815
23. M. Kowalczyk, M. Banach, and D.P. Mikhailidis Ticagrelor - A new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Med Sci Monit 15 2009 MS24 MS30
24. 12 receptor antagonist Ann Pharmacother 44 2010 524 537
25. K. Butler, and R. Teng Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment J Clin Pharmacol 52 2012 1388 1398
26. R.F. Storey, K.P. Bliden, and R. Ecob Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses J Thromb Haemost 9 2011 1730 1737
27. P.A. Gurbel, K.P. Bliden, and K. Butler Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study Circulation 120 2009 2577 2585
28. 12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol 50 2007 1852 1856
29. D. Alexopoulos, A. Galati, and I. Xanthopoulou Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: A pharmacodynamic study J Am Coll Cardiol 60 2012 193 199
30. 12 receptor antagonist Expert Opin Investig Drugs 18 2009 1219 1230
31. D.J. Angiolillo, R.C. Welsh, and D. Trenk Pharmacokinetic and pharmacodynamic effects of elinogrel: Results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial Circ Cardiovasc Interv 5 2012 347 356
32. K.A. Müller, T. Geisler, and M. Gawaz Elinogrel, an orally and intravenously available ADP-receptor antagonist. How does elinogrel affect a personalized antiplatelet therapy? Hamostaseologie 32 2012 191 194
33. E.D. Michos, R. Ardehali, and R.S. Blumenthal Aspirin and clopidogrel resistance Mayo Clin Proc 81 2006 518 526
34. V.L. Serebruany, S.R. Steinhubl, and P.B. Berger Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251
35. J. Daemen, P. Wenaweser, and K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study Lancet 369 2007 667 678
36. T.A. Nguyen, J.G. Diodati, and C. Pharand Resistance to clopidogrel: A review of the evidence J Am Coll Cardiol 45 2005 1157 1164
37. P.A. Gurbel, K.P. Bliden, and B.L. Hiatt Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
38. P.A. Gurbel, and K.P. Bliden Durability of platelet inhibition by clopidogrel Am J Cardiol 91 2003 1123 1125
39. P. Roy, L. Bonello, and R. Torguson Temporal relation between clopidogrel cessation and stent thrombosis after drug-eluting stent implantation Am J Cardiol 103 2009 801 805
40. K. Kolandaivelu, and D.L. Bhatt Overcoming 'resistance' to antiplatelet therapy: Targeting the issue of nonadherence Nat Rev Cardiol 7 2010 461 467
41. N. von Beckerath, D. Taubert, and G. Pogatsa-Murray Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial Circulation 112 2005 2946 2950
42. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy J Am Med Assoc 302 2009 849 857
43. D.L. Bhatt Tailoring antiplatelet therapy based on pharmacogenomics: How well do the data fit? J Am Med Assoc 302 2009 896 897
44. T. Bauer, H.J. Bouman, and J.W. van Werkum Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: Systematic review and meta-analysis Br Med J 343 2011 d4588
45. Z. Qureshi, and A.R. Hobson Clopidogrel "resistance": Where are we now? Cardiovasc Ther 2011 [Epub ahead of print]
46. F. Santilli, N. Vazzana, and R. Liani Platelet activation in obesity and metabolic syndrome Obes Rev 13 2012 27 42
47. C. Transon, T. Leemann, and P. Dayer In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors Eur J Clin Pharmacol 50 1996 209 215
48. D. Williams, and J. Feely Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors Clin Pharmacokinet 41 2002 343 370
49. W.C. Lau, L.A. Waskell, and P.B. Watkins Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction Circulation 107 2003 32 37
50. J. Saw, S.R. Steinhubl, and P.B. Berger Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial Circulation 108 2003 921 924
51. V.L. Serebruany, A.I. Malinin, and K.P. Callahan Statins do not affect platelet inhibition with clopidogrel during coronary stenting Atherosclerosis 159 2001 239 241
52. H. Wienbergen, A.K. Gitt, and R. Schiele Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies Am J Cardiol 92 2003 285 288
53. J.V. Mitsios, A.I. Papathanasiou, and F.I. Rodis Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes Circulation 109 2004 1335 1338
54. V.L. Serebruany, M.G. Midei, and A.I. Malinin Absence of interaction between atorvastatin or other statins and clopidogrel: Results from the interaction study Arch Intern Med 164 2004 2051 2057
55. J. Saw, D.M. Brennan, and S.R. Steinhubl Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial J Am Coll Cardiol 50 2007 291 295
56. D. Trenk, W. Hochholzer, and D. Frundi Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement Thromb Haemost 99 2008 174 181
57. N.S. Abraham Prescribing proton pump inhibitor and clopidogrel together: Current state of recommendations Curr Opin Gastroenterol 27 2011 558 564
58. S.L. Close Clopidogrel pharmacogenetics: Metabolism and drug interactions Drug Metabol Drug Interact 26 2011 45 51
59. H. Fernando, A.M. Dart, and K. Peter Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy Thromb Haemost 105 2011 933 944
60. J.L. Ferreiro, M. Ueno, and S.D. Tomasello Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: Results of a prospective, randomized, crossover study Circ Cardiovasc Interv 4 2011 273 279
61. R. Fontes-Carvalho, A. Albuquerque, and C. Araújo Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: A randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction Eur J Gastroenterol Hepatol 23 2011 396 404
62. A.M. Harmsze, A. de Boer, and H. Boot Interaction between clopidogrel and proton pump inhibitors Ned Tijdschr Geneeskd 155 2011 A2442
63. K. Hnid, and M. Chtioui Letter by Hnid and Chtioui regarding article, "Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: Results from the French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) Registry" Circulation 124 2011 e297
64. N.G. Hunfeld, V.E. Valkhoff, and D.J. Touw Clopidogrel and proton pump inhibitors: Insufficient evidence of interaction Ned Tijdschr Geneeskd 155 2011 A2404
65. J. Kwan, W.W. Htun, and Y. Huang Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention Vasc Health Risk Manag 7 2011 399 404
66. W.C. Lau, and P.A. Gurbel The drug-drug interaction between proton pump inhibitors and clopidogrel Can Med Assoc J 180 2009 699 700
67. S.D. Mistry, H.R. Trivedi, and D.M. Parmar Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence Indian J Pharmacol 43 2011 183 186
68. M.L. O'Donoghue, E. Braunwald, and E.M. Antman Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials Lancet 374 2009 989 997
69. B.W. Ogilvie, P. Yerino, and F. Kazmi The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: Implications for coadministration with clopidogrel Drug Metab Dispos 39 2011 2020 2033
70. L.C. Saiz, J. Alvarez, and H. Martínez Drug regulatory agencies' role in the interaction between clopidogrel and proton pump inhibitors Am J Gastroenterol 106 2011 1369 1370
71. I. Ulhaq, R. Sood, and V. Hegade Response to clopidogrel with proton pump inhibitors: Safe or not? Clin Cardiol 34 2011 721
72. M. Schmidt, M.B. Johansen, and D.J. Robertson Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation Aliment Pharmacol Ther 35 2012 165 174
73. M. Chen, J.F. Wei, and Y.N. Xu A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel Cardiovasc Ther 30 2012 e227 e233
74. S. Uchiyama Clopidogrel resistance: Identifying and overcoming a barrier to effective antiplatelet treatment Cardiovasc Ther 29 2011 e100 e111
75. T. Burkard, C.A. Kaiser, and H. Brunner-La Rocca Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: A report from the BASKET trial J Intern Med 271 2012 257 263
76. R.W. Harrison, and K.W. Mahaffey Clopidogrel and PPI interaction: Clinically relevant or not? Curr Cardiol Rep 14 2012 49 58
77. M.J. Price, S. Endemann, and R.R. Gollapudi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
78. P. Buonamici, R. Marcucci, and A. Migliorini Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis J Am Coll Cardiol 49 2007 2312 2317
79. L. Bonello, F. Paganelli, and M. Arpin-Bornet Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events J Thromb Haemost 5 2007 1630 1636
80. A.M. Gori, R. Marcucci, and A. Migliorini Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents J Am Coll Cardiol 52 2008 734 739
81. A. Migliorini, R. Valenti, and R. Marcucci High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease Circulation 120 2009 2214 2221
82. R. Marcucci, A.M. Gori, and R. Paniccia Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up Circulation 119 2009 237 242
83. N.J. Breet, J.W. van Werkum, and H.J. Bouman Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation J Am Med Assoc 303 2010 754 762
84. D.J. Angiolillo, E. Bernardo, and M. Sabaté Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease J Am Coll Cardiol 50 2007 1541 1547
85. T. Cuisset, C. Frere, and J. Quilici High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes Thromb Haemost 97 2007 282 287
86. T. Cuisset, C. Frere, and J. Quilici Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients Am J Cardiol 104 2009 1078 1082
87. G. Parodi, R. Marcucci, and R. Valenti High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI J Am Med Assoc 306 2011 1215 1223
88. D. Aradi, A. Komocsi, and A. Vorobcsuk Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis Am Heart J 160 2010 543 551
89. M.J. Price, P.B. Berger, and P.S. Teirstein Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial J Am Med Assoc 305 2011 1097 1105
90. P.A. Gurbel, and U.S. Tantry An initial experiment with personalized antiplatelet therapy: The GRAVITAS trial J Am Med Assoc 305 2011 1136 1137
91. D. Alexopoulos, A. Panagiotou, and I. Xanthopoulou Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity J Thromb Haemost 9 2011 2379 2385
92. D. Alexopoulos, I. Xanthopoulou, and P. Davlouros Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel Am Heart J 162 2011 733 739
93. D. Alexopoulos, G. Dimitropoulos, and P. Davlouros Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: The importance of CYP2C19*2 genotyping JACC Cardiovasc Interv 4 2011 403 410
94. I. Xanthopoulou, E.F. Stavrou, and G. Kassimis Resistance to high-maintenance dose of prasugrel treated by ticagrelor: A case report Platelets 2012 [Epub ahead of print]
95. H. Neubauer, A. Kaiser, and B. Busse Identification, evaluation and treatment of prasugrel low-response after coronary stent implantation - A preliminary study Thromb Res 126 2010 e389 e391
96. D.J. Angiolillo, J.J. Badimon, and J.F. Saucedo A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: Results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 trial Eur Heart J 32 2011 838 846
97. D. Alexopoulos Prasugrel resistance: Fact or fiction Platelets 23 2012 83 90
98. D.J. Angiolillo Applying platelet function testing in clinical practice: What are the unmet needs? J Am Med Assoc 306 2011 1260 1261
99. S. Yusuf, F. Zhao, and S.R. Mehta Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
100. M.S. Sabatine, C.P. Cannon, and C.M. Gibson Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY study J Am Med Assoc 294 2005 1224 1232
101. S.R. Steinhubl, P.B. Berger, and J.T. Mann Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial J Am Med Assoc 288 2002 2411 2420
102. S.R. Mehta, S. Yusuf, and R.J. Peters Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study Lancet 358 2001 527 533
103. S.R. Mehta, J.F. Tanguay, and J.W. Eikelboom Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial Lancet 376 2010 1233 1243
104. S.A. Murphy, E.M. Antman, and S.D. Wiviott Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial Eur Heart J 29 2008 2473 2479
105. D.A. Morrow, S.D. Wiviott, and H.D. White Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: An application of the classification system from the universal definition of myocardial infarction Circulation 119 2009 2758 2764
106. M.T. Roe, P.W. Armstrong, and K.A. Fox Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med 367 2012 1297 1309
107. C.P. Cannon, S. Husted, and R.A. Harrington Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial J Am Coll Cardiol 50 2007 1844 1851
108. C.P. Cannon, R.A. Harrington, and S. James Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): A randomised double-blind study Lancet 375 2010 283 293
109. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
110. R.A. Harrington, G.W. Stone, and S. McNulty Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2009 2318 2329
111. D.L. Bhatt, A.M. Lincoff, and C.M. Gibson Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2009 2330 2341
112. H.D. White, D.P. Chew, and H.L. Dauerman Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction Am Heart J 163 2012 182 190 e184
113. 12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: The INNOVATE-PCI trial Circ Cardiovasc Interv 5 2012 336 346
114. E.P. Navarese, M. Verdoia, and A. Schaffer Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: A meta-analysis of randomized trials QJM 104 2011 561 569
115. J.H. Kim, L.K. Newby, and R.M. Clare Clopidogrel use and bleeding after coronary artery bypass graft surgery Am Heart J 156 2008 886 892
116. J.S. Berger, C.B. Frye, and Q. Harshaw Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: A multicenter analysis J Am Coll Cardiol 52 2008 1693 1701
117. R.H. Hongo, J. Ley, and S.E. Dick The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting J Am Coll Cardiol 40 2002 231 237
118. R.H. Mehta, M.T. Roe, and J. Mulgund Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery J Am Coll Cardiol 48 2006 281 286
119. M.W. Chu, S.R. Wilson, and R.J. Novick Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 78 2004 1536 1541
120. W. Hochholzer, S.D. Wiviott, and E.M. Antman Predictors of bleeding and time dependence of association of bleeding with mortality: Insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) Circulation 123 2011 2681 2689
121. L.T. Goodnough, P.K. Smith, and J.H. Levy Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis J Thorac Cardiovasc Surg 2012 [Epub ahead of print]
122. P.M. Ho, E.D. Peterson, and L. Wang Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome J Am Med Assoc 299 2008 532 539
123. N. Sambu, T. Warner, and N. Curzen Clopidogrel withdrawal: Is there a "rebound" phenomenon? Thromb Haemost 105 2011 211 220
124. P.C. Armstrong, A.R. Dhanji, and A.T. Tucker Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy J Thromb Haemost 8 2010 613 615
125. J.A. Jakubowski, Y.G. Li, and C.D. Payne Absence of "rebound" platelet hyperreactivity following cessation of prasugrel Thromb Haemost 106 2011 174 176
126. R.S. Wright, J.L. Anderson, and C.D. Adams 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 123 2011 2022 2060
127. C.W. Hamm, J.P. Bassand, and S. Agewall ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
128. F.G. Kushner, M. Hand, and S.C. Smith 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 120 2009 2271 2306
129. G.N. Levine, E.R. Bates, and J.C. Blankenship 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the Society for Cardiovascular Angiography and Interventions Circulation 124 2011 e574 e651
130. R.C. Becker, J. Scheiman, and H.L. Dauerman Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures J Am Coll Cardiol 54 2009 2261 2276
131. J.D. Douketis, A.C. Spyropoulos, and F.A. Spencer Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e326S e3350
132. W. Wijns, P. Kolh, and N. Danchin Guidelines on myocardial revascularization Eur Heart J 31 2010 2501 2555
133. T.W. Rooke, A.T. Hirsch, and S. Misra 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 124 2011 2020 2045
134. R.L. Sacco, H.C. Diener, and S. Yusuf Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke N Engl J Med 359 2008 1238 1251
135. T.G. Brott, J.L. Halperin, and S. Abbara 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: Executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery Circulation 124 2011 489 532
136. L.S. Wann, A.B. Curtis, and C.T. January 2011 ACCF/AHA/HRS Focused Update on the Management of Patients with Atrial Fibrillation (updating the 2006 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 123 2011 104 123
137. O.C. Geraghty, N.L. Paul, and A. Chandratheva Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke Neurology 74 2010 1891 1896
138. S.J. Connolly, J.W. Eikelboom, and J. Ng Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable Ann Intern Med 155 2011 579 586
139. J.W. van Werkum, A.A. Heestermans, and A.C. Zomer Predictors of coronary stent thrombosis: The Dutch stent thrombosis registry J Am Coll Cardiol 53 2009 1399 1409
140. P.G. Perakis, T. Yunus, and G. Long Platelet function after cessation of chronic clopidogrel therapy Am Surg 78 2012 51 56
141. L. Broad, T. Lee, and M. Conroy Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery Br J Anaesth 98 2007 19 22
142. A.O. Abualsaud, and M.J. Eisenberg Perioperative management of patients with drug-eluting stents JACC Cardiovasc Interv 3 2010 131 142
143. C.M. Dyke, L.K. Jennings, and G. Maier Preoperative platelet inhibition with eptifibatide during coronary artery bypass grafting with cardiopulmonary bypass J Cardiovasc Pharmacol Ther 12 2007 54 60
144. J.D. Wessler, F. Saldana, and R.P. Giugliano Bridging therapy after recent stent implantation: Case report and review of data Cardiovasc Revasc Med 13 2012 30 38
145. W. Korte, M. Cattaneo, and P.G. Chassot Peri-operative management of antiplatelet therapy in patients with coronary artery disease: Joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC) Thromb Haemost 105 2011 743 749
146. S. Savonitto, M. D'Urbano, and M. Caracciolo Urgent surgery in patients with a recently implanted coronary drug-eluting stent: A phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel Br J Anaesth 104 2010 285 291
147. Cardiac Society of A, New Z Guidelines for the management of antiplatelet therapy in patients with coronary stents undergoing non-cardiac surgery Heart Lung Circ 19 2010 2 10
148. L.A. Fleisher, J.A. Beckman, and K.A. Brown ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing committee to revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery J Am Coll Cardiol 50 2007 1707 1732
149. V.A. Ferraris, S.P. Saha, and J.H. Oestreich 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations Ann Thorac Surg 94 2012 1761 1781
150. E.G. Marcos, A.C. Da Fonseca, and S.H. Hofma Bridging therapy for early surgery in patients on dual antiplatelet therapy after drug-eluting stent implantation Neth Heart J 19 2011 412 417
151. S. Savonitto, M. Caracciolo, and M. Cattaneo Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery J Thromb Haemost 9 2011 2133 2142
152. T. Ben Morrison, B.M. Horst, and M.J. Brown Bridging with glycoprotein IIb/IIIa inhibitors for periprocedural management of antiplatelet therapy in patients with drug eluting stents Catheter Cardiovasc Interv 79 2012 575 582
153. A.M. Pickett, D.A. Taylor, and M.L. Ackman Prolonged infusion of eptifibatide as bridge therapy between bare-metal stent insertion and cardiovascular surgery: Case report and review of the literature Pharmacotherapy 30 2010 127e 133e
154. S. Chou, S. Eshaghian, and A. Lamer Bridging therapy in the perioperative management of patients with drug-eluting stents Rev Cardiovasc Med 10 2009 209 218
155. A.N. Rassi, E. Blackstone, and M.A. Militello Safety of "bridging" with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery Am J Cardiol 110 2012 485 490
156. D.J. Angiolillo, M.S. Firstenberg, and M.J. Price Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: A randomized controlled trial J Am Med Assoc 307 2012 265 274
157. E.F. Carney Antiplatelet therapy: Can cangrelor bridge the gap to cardiac surgery? Nat Rev Cardiol 9 2012 128
158. T.T. Horlocker, D.J. Wedel, and J.C. Rowlingson Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition) Reg Anesth Pain Med 35 2010 64 101
159. W. Gogarten, E. Vandermeulen, and H. Van Aken Regional anaesthesia and antithrombotic agents: Recommendations of the European Society of Anaesthesiology Eur J Anaesthesiol 27 2010 999 1015
160. M.A. Anderson, T. Ben-Menachem, and S.I. Gan Management of antithrombotic agents for endoscopic procedures Gastrointest Endosc 70 2009 1060 1070
161. C.L. Grines, R.O. Bonow, and D.E. Casey Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians J Am Dent Assoc 138 2007 652 655
162. T. Lillis, A. Ziakas, and K. Koskinas Safety of dental extractions during uninterrupted single or dual antiplatelet treatment Am J Cardiol 108 2011 964 967
163. D.H. Stone, P.P. Goodney, and A. Schanzer Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery J Vasc Surg 54 2011 779 784
164. O. Chechik, Y. Goldstein, and E. Behrbalk Blood loss and complications following carotid endarterectomy in patients treated with clopidogrel Vascular 20 2012 193 197
165. S. Lavi, and R. Lavi Perioperative management of antiplatelet agents in patients undergoing cardiac surgery J Cardiothorac Vasc Anesth 26 2012 680 686
166. D.L. Bhatt, K.A. Fox, and W. Hacke Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 2006 1706 1717
167. R.J. Cerfolio, D.J. Minnich, and A.S. Bryant General thoracic surgery is safe in patients taking clopidogrel (Plavix) J Thorac Cardiovasc Surg 140 2010 970 976
168. L. Voltolini, C. Rapicetta, and L. Luzzi Lung resection for non-small cell lung cancer after prophylactic coronary angioplasty and stenting: Short- and long-term results Minerva Chir 67 2012 77 85
169. M. Sonobe, T. Sato, and F. Chen Management of patients with coronary stents in elective thoracic surgery Gen Thorac Cardiovasc Surg 59 2011 477 482
170. D.P. Ceppa, I.J. Welsby, and T.Y. Wang Perioperative management of patients on clopidogrel (Plavix) undergoing major lung resection Ann Thorac Surg 92 2011 1971 1976
171. O. Chechik, R. Thein, and G. Fichman The effect of clopidogrel and aspirin on blood loss in hip fracture surgery Injury 42 2011 1277 1282
172. J.M. Christy, S.P. Stawicki, and A.M. Jarvis The impact of antiplatelet therapy on pelvic fracture outcomes J Emerg Trauma Shock 4 2011 64 69
173. P.F. Dineen, R.J. Curtin, and J.A. Harty A review of the use of common antiplatelet agents in orthopaedic practice J Bone Joint Surg Br 92 2010 1186 1191
174. J.A. Nydick, E.D. Farrell, and A.J. Marcantonio The use of clopidogrel (Plavix) in patients undergoing nonelective orthopaedic surgery J Orthop Trauma 24 2010 383 386
175. S. Nandi, M. Aghazadeh, and C. Talmo Perioperative clopidogrel and postoperative events after hip and knee arthroplasties Clin Orthop Relat Res 470 2012 1436 1441
176. J.O. Mason, S.R. Gupta, and C.J. Compton Comparison of hemorrhagic complications of warfarin and clopidogrel bisulfate in 25-gauge vitrectomy versus a control group Ophthalmology 118 2011 543 547
177. J. Oh, W.E. Smiddy, and S.S. Kim Antiplatelet and anticoagulation therapy in vitreoretinal surgery Am J Ophthalmol 151 2011 934 939 e933
178. S.K. Law, B.J. Song, and F. Yu Hemorrhagic complications from glaucoma surgery in patients on anticoagulation therapy or antiplatelet therapy Am J Ophthalmol 145 2008 736 746
179. A. Descazeaud, G. Robert, and S. Lebdai Impact of oral anticoagulation on morbidity of transurethral resection of the prostate World J Urol 29 2011 211 216
180. S. Lebdai, G. Robert, and M. Devonnec Management of patients under anticoagulants for transurethral resection of the prostate: a multicentric study by the CTMH-AFU Prog Urol 19 2009 553 557
181. O.T. Halliwell, G. Yadegafar, and C. Lane Transrectal ultrasound-guided biopsy of the prostate: Aspirin increases the incidence of minor bleeding complications Clin Radiol 63 2008 557 561
182. D. Eberli, P.G. Chassot, and T. Sulser Urological surgery and antiplatelet drugs after cardiac and cerebrovascular accidents J Urol 183 2010 2128 2136
183. J.C. Kefer, M.M. Desai, and A. Fergany Outcomes of partial nephrectomy in patients on chronic oral anticoagulant therapy J Urol 180 2008 2370 2374 discussion:2734
184. J.C. Kefer, B. Turna, and R.J. Stein Safety and efficacy of percutaneous nephrostolithotomy in patients on anticoagulant therapy J Urol 181 2009 144 148
185. G. Mukerji, I. Munasinghe, and A. Raza A survey of the peri-operative management of urological patients on clopidogrel Ann R Coll Surg Engl 91 2009 313 320